ClinicalTrials.gg
CompletedNCT00143026Updated Mar 29, 2017

Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States

A Phase 4 interventional study of carbidopa, levodopa, entacapone in Parkinson's Disease, sponsored by Novartis. Completed at 18 sites in 4 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2017-03-29.

Sponsored by Novartis · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing carbidopa in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. Carbidopa · Parkinson Disease.

Enrollment
5th of 24
184 · median 46
Started
2005
with 2 others
Phase 4
9 of 24
1 open now
Registered
4th of 24
by date
Lead sponsor
4 of 24
Novartis

Among the 24 studies testing carbidopa in Parkinson Disease, this one is the 5th largest by enrollment, is one of 3 that started in 2005, is one of 9 in phase 4, and was the 4th registered.

Parkinson Disease

4,576 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 24 studies testing carbidopa in Parkinson Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About carbidopa

Carbidopa: first FDA approval 1975 (SINEMET), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing carbidopa in Parkinson Disease, or all of them as a file.
02

Study summary

This study examines the effect of treatment of levodopa/entacapone on quality of life, as measured by the Parkinson's Disease-Questionnaire 8 (PDQ-8), in Parkinson's disease patients with no or minimal, non-disabling motor fluctuations.

Read the detailed description

This study examines the effect of treatment of levodopa/entacapone on quality of life, as measured by the Parkinson's Disease-Questionnaire 8 (PDQ-8), in Parkinson's disease patients with no or minimal, non-disabling motor fluctuations. Treatment with carbidopa/levodopa/entacapone will be compared with treatment with standard formulation levodopa/carbidopa.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Parkinson's disease, levodopa, motor fluctuations
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of idiopathic Parkinson's disease exhibiting at least 2 or 3 symptoms
  • Motor functions must be regarded as non-disabling by the patient

Exclusion criteria

Exclusion Criteria:

  • History, signs or symptoms suggesting the diagnosis of atypical or secondary parkinsonism
  • History of dyskinesia
  • Previous or current use of entacapone or tolcapone
  • Unstable Parkinson's disease patients requiring/receiving regimens of levodopa
  • Subjects taking levodopa/DDCI controlled release or extended release formulations
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
184 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Quality of life assessment

Secondary outcomes

  1. Symptom control change from baseline

  2. Change from baseline in number of wearing-off symptoms

  3. Change from baseline in proportion of patients experiencing wearing-off

07

Study locations

18 sites
  • Royal Adelaide Hospital
    Adelaide, Australia
  • Watkins Medical Center
    Brisbane, Australia
  • Central Coast Neuroscience Research
    Gosford, Australia
  • Heidelberg Repatriation Hospital
    Melbourne, Australia
  • Monash Medical Centre
    Melbourne, Australia
  • Sir Charles Gairdner Hospital
    Perth, Australia
  • Concord Hospital
    Sydney, Australia
  • Southern Neurology, St. George Private Hospital
    Sydney, Australia
  • Westmead Hospital
    Sydney, Australia
  • St. Luke's Medical Centre
    Manila, Philippines
  • University of Santo Tomas Hospital
    Manila, Philippines
  • Chang Gung Memorial Hospital
    Linkou, Taiwan
  • Kaohsiung Medical University, Chung-Ho Memorial Hospital
    Linkou, Taiwan
  • National Taiwan University Hospital
    Linkou, Taiwan
  • King Chulalongkorn Memorial Hospital
    Bangkok, Thailand
  • Maharaj Nakorn Chiangmai Hospital
    Bangkok, Thailand
  • Siriraj Hospital
    Bangkok, Thailand
  • Pharmongkutklao Army Hospital
    Bankok, Thailand
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2005
First posted
Sep 2, 2005
Start
Jul 2005
Primary completionActual
Jun 2006
CompletionActual
Jun 2006
Last update
Mar 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00143026
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Sep 2, 2005
Start date
Jul 2005
Primary completion
Jun 2006
Completion
Jun 2006
Last update
Mar 29, 2017

Study contacts

Novartis Pharmaceuticals
study chair
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carbidopa · Levodopa · Entacapone

Start the discussion